Biotech start-up set to become world-leader in "Drug Interaction Profiling"

Sheffield based Retrogenix Ltd is developing an exciting new technology that will make a major impact at all levels of the drug discovery and development stages, and potentially open up new markets for existing product lines for the world’s major pharmaceutical companies.
The technology which is known as Cell Microarray will enable the pharmaceutical industry to determine the mechanism of action of pharmaceutical drugs or candidate drugs.

Jim Freeth, MD of Retrogenix said: “The new technology will provide clients with a powerfutool to be used across a range of areas in their product development cycle, from identifying novel drug targets, to understanding toxic side effects of drugs in clinical trials, to uncovering new opportunities for these drugs.”
 
Retrogenix have recently moved into their new lab at the Sheffield Bioincubator which houses over £300,000 of state-of-the-art equipment donated by Astra Zeneca.
Jim continued: “Thanks to the fantastic support we’ve received from Astra Zeneca, and the Innovation Centres team at the University of Sheffield I’m confident we will build a highly valuable and sought after biotechnology business and be successful in bringing this exciting technology to market”.